March 30 (Reuters) - WPD Pharmaceuticals Inc WBIO.CD :* WPD PHARMACEUTICALS ANNOUNCES AMENDED SUBLICENSE AGREEMENT WITH MOLECULIN BIOTECH FOR WP1066, WP1122 AND ANNAMYCIN DRUG...
Feb 11 (Reuters) - WPD Pharmaceuticals Inc WBIO.CD :* WPD PHARMACEUTICALS ENGAGES WORLDWIDE CLINICAL TRIALS AS CRO FOR FURTHER SUPPORT ON BERUBICIN TRIALS
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Neutral | Sell | Sell | Sell | Strong Sell |
| Technical Indicators | Buy | Strong Buy | Strong Buy | Strong Sell | Strong Sell |
| Summary | Neutral | Neutral | Neutral | Strong Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 9.37 | 9.46 | 9.07 | +0.15 | +1.63% | 16.17K | Toronto | |||
| 58.74 | 59.48 | 58.18 | -0.85 | -1.43% | 1.69M | Toronto | |||
| 27.76 | 27.87 | 27.51 | -0.29 | -1.03% | 2.70M | Toronto | |||
| 44.85 | 45.96 | 44.56 | +0.75 | +1.70% | 165.19K | CSE | |||
| 52.58 | 54.31 | 52.50 | -1.42 | -2.63% | 72.73K | Toronto | |||
| 126.00 | 126.91 | 124.01 | +1.05 | +0.84% | 81.58K | Toronto | |||
| 58.80 | 59.43 | 58.31 | -0.08 | -0.14% | 1.32M | Toronto | |||
| 54.00 | 54.42 | 53.42 | +0.25 | +0.47% | 691.44K | Toronto | |||
| 149.99 | 153.40 | 149.85 | -1.58 | -1.04% | 65.78K | Toronto | |||
| 6.76 | 6.91 | 6.47 | 0.00 | 0.00% | 0.00 | Toronto | |||
| 0.405 | 0.00 | 0.00 | -0.0100 | -2.41% | 241.06K | Toronto | |||
| 60.83 | 61.43 | 60.83 | 0.00 | 0.00% | 0.00 | Toronto | |||
| 0.075 | 0.00 | 0.00 | +0.005 | +7.14% | 116.50K | TSXV | |||
| 60.92 | 61.18 | 60.66 | -0.29 | -0.47% | 4.11M | Toronto | |||
| 196.48 | 198.88 | 194.46 | -3.13 | -1.57% | 392.56K | Toronto |
WPD Pharmaceuticals Inc, formerly Westcot Ventures Corp, is a Canada-based biotechnology research and development company. The Company focuses on oncology, research and development of medicinal products involving biological compounds and small molecules. The Company has approximately 10 drug candidates with five that are in clinical development stage and five in pre-clinical development. The Company’s drug development focuses on melanoma, brain cancer, leukemia and pancreatic cancer. Its portfolio for brain cancer includes WPD101, Berubicin and WP1066. Its portfolio for pancreatic cancer includes WP1066 and WP1732. Its portfolio for other cancers include WPD103, WP1220 and Annamycin.